Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: Efficacy, safety and patient selection

Functional Neurology

Volumn 27, Issue 3, 2012, Pages 147-154

  Abbruzzese, Giovanni ^a   Barone, Paolo ^b   Bonuccelli, Ubaldo ^c   Lopiano, Leonardo ^d   Antonini, Angelo ^e  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

Continuous dopaminergic stimulation; Deep brain stimulation; Levodopa carbidopa intestinal gel infusion; Parkinson's disease; Patient selection

Indexed keywords

APOMORPHINE; CARBIDOPA PLUS LEVODOPA; CYANOCOBALAMIN; DOMPERIDONE; DOPAMINE; FOLIC ACID; HOMOCYSTEINE; LEVODOPA;

ARTICLE; BRAIN DEPTH STIMULATION; CENTRAL NERVOUS SYSTEM INFECTION; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FOLLOW UP; HUMAN; MOTOR DYSFUNCTION; MULTICENTER STUDY (TOPIC); NAUSEA AND VOMITING; PARKINSON DISEASE; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PSYCHOSIS; PUBLICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SCORING SYSTEM; SOMNOLENCE; SUBTHALAMIC NUCLEUS; SURVIVAL RATE;

AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DECISION MAKING; HUMANS; INFUSIONS, PARENTERAL; INTUBATION, GASTROINTESTINAL; LEVODOPA; PARKINSON DISEASE; PATIENT SELECTION;

EID: 84873663005     PISSN: 03935264     EISSN: 19713274     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease. CNS Drugs 2010; 24:119-129.
2. Stocchi F, Jenner P, Obeso JA. When do levodopa motor fluctuations first appear in Parkinson's disease? Eur Neurol 2010;63:257-266.
3. Tetrud JW. Balancing short-term symptom control and long-term functional outcomes in patients with Parkinson's disease. CNS Spectr 2007;12:275-286.
4. Abruzzese G, Albanese A, Antonini A et al. Linee Guida per il trattamento della Malattia di Parkinson 2002. Neurol Sci 2002;23:S1-S63.
5. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007;22: 1379-1389.
6. Weintraub D, Comella CL, Horn S. Parkinson's disease-Part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care 2008;14:S40-S48.
7. Stocchi F, Tagliati M, Olanow CW. Treatment of levodopa- induced motor complications. Mov Disord 2008; 23:S559-S612.
8. Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 2010;5:229-238.
9. Zappia M, Montesanti R, Colao R, Quattrone A. Usefulness of movement time in the assessment of Parkinson's disease. J Neurol 1994;241:543-550.
10. Nutt JG, Carter JH, Van Honten L, Woodward WR. Short and long duration response to levodopa during the first year of levodopa therapy. Ann Neurol 1997;42:349-355.
11. Zappia M, Bosco D, Plastino M et al. Pharmacodynamics of the long duration response to levodopa in PD. Neurology 1999;53:557-560.
12. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005;20:224-230.
13. Antonini A, Barone P, Marconi R et al. The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. J Neurol 2012;259:2621-2631.
14. The Deep Brain Stimulation for Parkinson's Disease Study Group. Deep brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001:345;956-963.
15. Kleiner-Fisman Y, Herzog J, Fisman DN et al. Subthalamic nucleus deep brain stimulation: summary and metaanalysis of outcomes. Mov Disord 2006;21:S290-S304.
16. Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999;14: 572-584.
17. Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinsons' disease. Lancet Neurol 2009;8:67-81.
18. Cilia R, Marotta G, Landi A et al. Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: a prospective case-control study. Clin Neurol Neurosurg 2009;111:140-146.
19. Hariz M. Deep brain stimulation versus best medical therapy for advanced Parkinson's disease. Lancet Neurol 2009;8:223-224.
20. Lang AE, Houeto JL, Krack P et al. Deep brain stimulation: preoperative issues. Mov Disord 2006;21:S171-S196.
21. Moro E, Lozano AM, Pollak P et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord 2010;25:578-586.
22. Follett KA, Weaver FM, Stern M et al. Pallidal versus subthalamic deep brain stimulation for Parkinson's disease. N Engl J Med 2010;362:2077-2091.
23. Fasano A, Romito LM, Daniele A et al. Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain 2010;133:2664-2676.
24. Antonini A, Isaias IU, Rodolfi G et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 2011;258:579-585.
25. Tripoliti E, Zrinzo L, Martinez-Torres I et al. Effects of subthalamic stimulation on speech of consecutive patients with Parkinson disease. Neurology 2011;76:80-86.
26. Antonini A, Ursino G, Calandrella D, Bernardi D, Plebani M. Continuous dopaminergic delivery in Parkinson's disease. J Neurol 2010; 257 (Suppl 2):305-308.
27. Antonini A, Odin P. Pros and cons of apomorphine and Ldopa continuous infusion in advanced Parkinson's disease. Parkinsonism Relat Disord 2009;15:S97-100.
28. Haq IU, Lewitt PA, Fernandez HH. Apomorphine therapy in Parkinson's disease. Exp Opin Pharmacother 2007;8: 2799-2809.
29. Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. Curr Med Res Opin 2011;27:907-919.
30. Stocchi F, Vacca, L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910.
31. Nyholm D, Askmark H, Gomes-Trolin C et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained release tablets. Clin Neuropharmacol 2003;26: 156-163.
32. Nutt JG. Continuous dopaminergic stimulation: is it the answer to the motor complication of levodopa? Mov Disord 2007;22:1-9.
33. Nyholm D, Nilsson Remahl AI, Dizdar N et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-223.
34. Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:657-664.
35. Eggert K, Schrader C, Hahn M et al. Continuous jejunal levodopa infusion in patients with advanced Parkinson's disease. Practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151-166.
36. Antonini A, Isaias IU, Canesi M et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-1149.
37. Antonini A, Bondiolotti G, Natuzzi F, Bareggi SR. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. Eur Neuropsychopharmacol 2010; 20: 683-687.
38. Puente V, De Fabregues O, Oliveras C et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's' disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 2010;16:218-221.
39. Merola A, Zibetti M, Angrisano S, Rizzi L, Lanotte M, Lopiano L. Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease. Mov Disord 2011;26:664-670.
40. Antonini A, Mancini F, Canesi M et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 2008;5:244-246.
41. Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundquist C, Aquilonius SM. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008;31:63-73.
42. Devos D; French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009;24:993-1000.
43. Honig H, Antonini A, Martinez-Martin P et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-1474.
44. Hariz MI. Complications of deep brain stimulation surgery. Mov Disord 2002;17 Suppl 3:S162-S166.
45. Deuschl G, Herzog J, Kleiner-Fisman G et al. Deep brain stimulation: postoperative issues. Mov Disord 2006;21 Suppl 14:S219-S237.
46. Toth C, Breithaupt K, Ge S et al. Levodpopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 2010;68:28-36.
47. Muller T, Jugel C, Ehret R et al. Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel. J Neural Transm 2011;118:1329-1333.
48. Santos-Garcia D, Macias M, Llaneza M, Grande M, de la Fuente-Fernandez R. Serum vitamin B (12) and folate levels in Parkinson's disease patients treated with duodenal levodopa infusion. Mov Disord 2011;26:558-559.
49. Urban PP, Wellach I, Faiss S et al. Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord 2010; 25:1748-1752.
50. Klostermann F, Jugel C, Muller T, Marzinzik F. Malnutritional neuropathy under intestinal levodopa infusion. J Neural-Transm 2012;119:369-372.
51. Antonini A, Tolosa E. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. Expert Rev Neurother 2009;9:859-867.
52. DANMODIS, Danish Movement Disorder Society; SWEMODIS, Swedish Movement Disorder Society. Duodopa: Scandinavian Consensus I. Treatment with levodopa/carbidopa gel (DuodopaR) in patients with Parkinson's disease, 2008. Available at http://info.parkinsonforbundet.se/wp-content/uploads/duodopakonsensus-20081.pdf.
53. Lowin J, Bergman A, Chauduri KR et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK. J Med Econ 2011;14:584-593.
54. Reese JP, Dams J, Winter Y, Balzer-Geldsetzer M, Oertel WH, Dodel R. Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease. Expert Opin Pharmacother 2012;13:939-958.